Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Buchdunger

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Biochimica Et Biophysica Acta|September 13, 2001
Bcr-Abl inhibition as a modality of CML therapeuticsE Buchdunger, A Matter, B J Druker
Transplantation Proceedings|March 20, 1999
Inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitorE Kallio, P Koskinen, E Buchdunger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growthG W Krystal, S Honsawek, J Litz, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 21, 1997
Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferationM Myllärniemi, L Calderon, K Lemström, et al.
Transplantation Proceedings|March 20, 1999
Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptorP Koskinen, R Sihvola, M Myllärniemi, et al.
Journal De Pharmacie De Belgique|March 1, 1997
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-RP Traxler, P Furet, H Mett, et al.
Journal of Medicinal Chemistry|June 7, 1996
4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinaseP M Traxler, P Furet, H Mett, et al.
Cardiovascular Drugs and Therapy|June 18, 1999
Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivoM Myllärniemi, J Frösen, L G Calderón Ramirez, et al.
Circulation|May 5, 1999
Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptorR Sihvola, P Koskinen, M Myllärniemi, et al.
British Journal of Cancer|April 16, 2002
Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's diseaseD Re, C Wickenhauser, T Ahmadi, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Biochimica Et Biophysica Acta|September 13, 2001
Bcr-Abl inhibition as a modality of CML therapeuticsE Buchdunger, A Matter, B J Druker
Transplantation Proceedings|March 20, 1999
Inhibition of obliterative bronchiolitis by platelet-derived growth factor receptor protein-tyrosine kinase inhibitorE Kallio, P Koskinen, E Buchdunger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growthG W Krystal, S Honsawek, J Litz, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 21, 1997
Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferationM Myllärniemi, L Calderon, K Lemström, et al.
Transplantation Proceedings|March 20, 1999
Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptorP Koskinen, R Sihvola, M Myllärniemi, et al.
Journal De Pharmacie De Belgique|March 1, 1997
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-RP Traxler, P Furet, H Mett, et al.
Journal of Medicinal Chemistry|June 7, 1996
4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinaseP M Traxler, P Furet, H Mett, et al.
Cardiovascular Drugs and Therapy|June 18, 1999
Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivoM Myllärniemi, J Frösen, L G Calderón Ramirez, et al.
Circulation|May 5, 1999
Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptorR Sihvola, P Koskinen, M Myllärniemi, et al.
British Journal of Cancer|April 16, 2002
Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's diseaseD Re, C Wickenhauser, T Ahmadi, et al.
Pageof 5